Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2021-04-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于控股子公司签订《产品技术转移和生产协议》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 华兰生物工程股份有限公司 regarding the signing of a 'Product Technology Transfer and Production Agreement' by its controlling subsidiary. It details the agreement terms, risks, and future plans related to vaccine production technology transfer and development. The document includes information about the contracting parties, contract terms, and impact on the company, but it does not contain financial statements, earnings data, or detailed financial analysis. It is a corporate announcement about a business agreement and related risks, not a financial report or regulatory filing of financial results. The document length is 1961 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into more specific categories like earnings release, capital update, or management report.
2021-04-19 Chinese
关于签订《产品委托开发及生产协议》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a related-party transaction agreement for product development and production between the company and its related entities. It details the nature of the transaction, the parties involved, approvals by the board and independent directors, and compliance with regulatory requirements. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is a formal disclosure of a related-party transaction, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a corporate transaction that does not fall into other specific categories like M&A or Capital Updates.
2021-04-19 Chinese
第七届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 华兰生物工程股份有限公司, detailing the decisions made at the 15th meeting of the 7th Board of Directors. It includes voting results and references to related announcements published elsewhere. The content focuses on board decisions and related transactions, with no financial statements or detailed management discussion. The document length is short (586 characters), and it is an announcement of board resolutions rather than a full report. Therefore, it fits best under Board/Management Information (MANG).
2021-04-19 Chinese
关于举行2020年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is a short announcement (654 characters) about the scheduling of a 2020 annual performance briefing (业绩说明会) to be held online on April 19, 2021. It invites investors to participate and submit questions in advance. There is no detailed financial data or report content included, only an announcement of the event. According to the 'Menu vs Meal' rule, this is not the actual performance report but an announcement about the event where the report will be discussed. Therefore, it fits best as an Investor Presentation (IP) announcement or possibly a Report Publication Announcement (RPA). However, since it specifically refers to an '业绩说明会' (performance briefing), which is a form of investor presentation, the classification as Investor Presentation (IP) is most appropriate.
2021-04-13 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit operations, information disclosure, insider trading controls, fundraising, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings such as audit reports or annual reports. It is also not an announcement or notice but an internal control compliance document. Therefore, it best fits the category of Regulatory Filings (RNS) as a general compliance document that does not fit other specific categories.
2021-03-29 Chinese
独立董事对担保等事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion report on various company matters including related party transactions, external guarantees, internal control evaluation, appointment of the audit firm for the next year, investment and financing opinions, profit distribution plans, shareholder return plans, and appointment of senior management. It references compliance with laws, regulations, and company articles, and provides independent opinions on these governance and financial oversight matters. The document is not a full annual report, audit report, or financial statement, but rather a formal independent directors' statement on governance and audit-related issues. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure document that does not fit other specific categories like Annual Report or Audit Report. The document length is short (3155 characters) and it is a formal opinion statement rather than a report or announcement of a report publication.
2021-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.